Aug 7, 2024 06:00AM
May 8, 2024 06:00AM
Feb 29, 2024 10:02AM
Feb 27, 2024 06:02AM
Feb 27, 2024 06:00AM
Feb 26, 2024 06:00AM
Nov 9, 2023 04:01PM BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
Sep 19, 2023 06:15AM
Sep 19, 2023 06:15AM
Aug 2, 2023 06:00AM
Jul 12, 2023 07:03AM
Jul 12, 2023 07:00AM
Nov 9, 2022 07:00AM
Aug 4, 2022 07:00AM BeiGene Reports Second Quarter 2022 Financial Results
Jul 14, 2022 06:00AM
Jul 14, 2022 06:00AM
Jun 22, 2022 07:21AM
Jun 13, 2022 07:00AM
Jun 13, 2022 07:00AM
May 5, 2022 07:00AM
Apr 11, 2022 06:01AM BeiGene (BGNE) Announces IRC Determined BRUKINSA Demonstrated Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
Apr 11, 2022 06:00AM
Mar 11, 2022 07:01AM
Mar 11, 2022 07:00AM
Feb 25, 2022 07:00AM
Feb 22, 2022 07:01AM
Feb 22, 2022 07:01AM
Feb 22, 2022 07:00AM BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia
Jan 24, 2022 05:52AM
Jan 24, 2022 05:00AM
Jan 6, 2022 06:38AM
Jan 6, 2022 03:30AM
Dec 20, 2021 06:15AM
Dec 20, 2021 06:15AM
Dec 10, 2021 06:15AM BeiGene (BGNE) Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO
Dec 10, 2021 03:00AM
Dec 3, 2021 05:36AM
Dec 2, 2021 11:00PM
Nov 4, 2021 04:05PM
Sep 13, 2021 06:18AM
Sep 13, 2021 12:00AM
Aug 5, 2021 04:05PM BeiGene Reports Second Quarter 2021 Financial Results
May 19, 2021 07:01AM
May 19, 2021 07:00AM
Feb 25, 2021 04:05PM
Feb 17, 2021 07:05AM
Feb 17, 2021 07:00AM
Nov 12, 2019 04:05PM
Aug 21, 2019 04:30PM BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Jul 27, 2017 07:30AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All